GlassScriptPhysician profile
Steven C Boysel
NPI 1811981723
$2,975.08
in general payments reported to CMS, 2019-2025
23 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.73 · 2023: $482 · 2024: $1,097 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,943.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $884.67 | 2023-2025 | Ubrelvy, Vraylar, Qulipta |
| Abbott Laboratories | $532.49 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $406.18 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $140.63 | 2024-2025 | Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $105.51 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $104.56 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Corium, LLC | $91.58 | 2023-2025 | Azstarys |
| Dexcom, INC. | $91.22 | 2023-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $87.04 | 2025 | Sunosi, Symbravo, Auvelity |
| Lilly USA, LLC | $86.09 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $75.94 | 2024-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Exact Sciences Corporation | $74.93 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $69.78 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $44.99 | 2023-2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $34.34 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.30 | 2025 | Caplyta |
| Radius Health, INC. | $21.81 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $18.70 | 2023 | |
| Ani Pharmaceuticals, INC. | $17.18 | 2023 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $15.52 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.07 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.18 | 2024 | Trulance, Xifaxan |
| Tris Pharma INC | $13.37 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Boysel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.